Last reviewed · How we verify
Pentabio
At a glance
| Generic name | Pentabio |
|---|---|
| Also known as | DTP-HB-Hib Vaccine |
| Sponsor | PT Bio Farma |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) (PHASE3)
- Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B (PHASE3)
- Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV (PHASE4)
- Safety Profile Following Pentabio Vaccination in Indonesian Infants
- Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pentabio CI brief — competitive landscape report
- Pentabio updates RSS · CI watch RSS
- PT Bio Farma portfolio CI